GlassScriptPhysician profile
Richard Daniel Blair
NPI 1386646628
$13,262.38
in general payments reported to CMS, 2019-2025
32 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $463 · 2021: $873 · 2022: $1,513 · 2023: $1,078 · 2024: $8,163 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $8,194 · Food and Beverage: $1,488 · Consulting Fee: $180 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $8,194.45 |
| Food and Beverage | $1,487.78 |
| Consulting Fee | $180.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $8,194.45 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $1,112.64 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $555.30 | 2019-2025 | Jynarque |
| Amgen INC. | $503.30 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Nxstage Medical, INC. | $391.66 | 2024-2025 | Nxstage System One |
| Glaxosmithkline, LLC. | $388.01 | 2021-2024 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $320.46 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $198.56 | 2019-2024 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $158.02 | 2019-2025 | Brilinta |
| Cumberland Pharmaceuticals, INC. | $143.73 | 2021 | |
| Opko Pharmaceuticals, LLC | $137.58 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $127.22 | 2020-2024 | Conquest |
| Horizon Therapeutics Plc | $125.97 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $98.31 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $92.21 | 2021-2025 | Ultomiris |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $87.49 | 2022-2025 | |
| Philips North America LLC | $83.30 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $68.70 | 2025 | |
| Travere Therapeutics, INC. | $62.57 | 2023-2025 | |
| Novo Nordisk INC | $53.17 | 2024-2025 | Wegovy, Rivfloza |
| Merck Sharp & Dohme LLC | $42.27 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $40.75 | 2020 | |
| Ardelyx, INC. | $40.49 | 2025 | Ibsrela |
| Becton, Dickinson and Company | $39.00 | 2023 | |
| Akebia Therapeutics INC | $35.89 | 2020-2021 | |
| Daiichi Sankyo INC. | $34.13 | 2021-2022 | |
| Lilly USA, LLC | $33.35 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.74 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $20.93 | 2024 | |
| Tactile Systems Technology INC | $14.90 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $13.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.